Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Black Diamond Therapeutics, Inc.BDTX · Entity 6669 | Director | June 26, 2026 | June 29, 2026 |
| CRISPR Therapeutics AGCRSP · Entity 3852 | Director · Chief Executive Officer | October 13, 2026 | October 15, 2026 |
| Oruka Therapeutics, Inc.ORKA · Entity 3781 | Director | June 02, 2026 | June 03, 2026 |
| Repare Therapeutics Inc.RPTX · Entity 68433 | Director | June 17, 2024 | June 20, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Black Diamond Therapeutics, Inc.
Report date June 26, 2026 · Filed June 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.71 · Expires 2036-06-25 | Direct | 40,000 |
Reported balance
After 2026-06-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-26 · Grant · Acquired 40,000 · Balance 40,000 F1: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 26, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 26, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.
CRISPR Therapeutics AG
Report date October 13, 2026 · Filed October 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 259,736 |
Ending reported balance
After 2026-10-14 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-13 · Exercise / conversion · Acquired 8,333 · Balance 263,834 F1: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Row 2 · 2026-10-14 · Sale · Disposed 4,098 · Balance 259,736 F2: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-10-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-13 · Exercise / conversion · Disposed 8,333 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3: This restricted stock unit award was granted on October 13, 2023 with respect to 25,000 Common Shares, with (i) one third of the shares vesting on October 13, 2024, (ii) one third of the shares vesting on October 13, 2025, and (iii) one third of the shares vesting on October 13, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F2: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
F3: This restricted stock unit award was granted on October 13, 2023 with respect to 25,000 Common Shares, with (i) one third of the shares vesting on October 13, 2024, (ii) one third of the shares vesting on October 13, 2025, and (iii) one third of the shares vesting on October 13, 2026.
Oruka Therapeutics, Inc.
Report date June 02, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $55.23 · Expires 2036-06-01 | Direct | 9,136 |
Reported balance
After 2026-06-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-02 · Grant · Acquired 9,136 · Balance 9,136 F1: The option vests as to 1/12 of the underlying shares monthly from June 2, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 1/12 of the underlying shares monthly from June 2, 2026.
Repare Therapeutics Inc.
Report date June 17, 2024 · Filed June 20, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.80 · Expires 2034-06-16 | Direct | 27,200 |
Reported balance
After 2024-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-17 · Grant · Acquired 27,200 · Balance 27,200 F1: The option will vest in equal monthly installments over twelve (12) months from the date of grant, subject to Reporting Person continuing to provide service through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest in equal monthly installments over twelve (12) months from the date of grant, subject to Reporting Person continuing to provide service through each such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Centessa Pharmaceuticals plc
Report date June 24, 2026 · Filed June 24, 2026
Section 16 reporting ended · disclosed 2026-06-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.84 · Expires 2031-02-19 | Direct | 0 |
Reported balance
After 2026-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-24 · Disposition to issuer · Disposed 208,474 · Balance 0 F1: On June 24, 2026, Eli Lilly and Company ("Parent"), through its wholly owned subsidiary LDH XV Corporation ("Purchaser"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the "Company") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the "Transaction Agreement"). F2: Pursuant to the Transaction Agreement, at the effective time of the Scheme of Arrangement, each outstanding share option, whether or not vested, was automatically cancelled and converted into the right to receive (i) an amount in cash equal to the excess of $38.00 in cash over the per-share exercise price of such option, without interest and less any applicable withholding taxes, and (ii) one non-transferable contingent value right (a "CVR") per underlying Ordinary Share entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent, in each case in accordance with the Transaction Agreement. No share options were exercised prior to the Effective Time. F3: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.87 · Expires 2032-06-30 | Direct | 0 |
Reported balance
After 2026-06-24 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-24 · Disposition to issuer · Disposed 48,000 · Balance 0 F1: On June 24, 2026, Eli Lilly and Company ("Parent"), through its wholly owned subsidiary LDH XV Corporation ("Purchaser"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the "Company") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the "Transaction Agreement"). F2: Pursuant to the Transaction Agreement, at the effective time of the Scheme of Arrangement, each outstanding share option, whether or not vested, was automatically cancelled and converted into the right to receive (i) an amount in cash equal to the excess of $38.00 in cash over the per-share exercise price of such option, without interest and less any applicable withholding taxes, and (ii) one non-transferable contingent value right (a "CVR") per underlying Ordinary Share entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent, in each case in accordance with the Transaction Agreement. No share options were exercised prior to the Effective Time. F3: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.35 · Expires 2033-06-22 | Direct | 0 |
Reported balance
After 2026-06-24 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-24 · Disposition to issuer · Disposed 48,000 · Balance 0 F1: On June 24, 2026, Eli Lilly and Company ("Parent"), through its wholly owned subsidiary LDH XV Corporation ("Purchaser"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the "Company") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the "Transaction Agreement"). F2: Pursuant to the Transaction Agreement, at the effective time of the Scheme of Arrangement, each outstanding share option, whether or not vested, was automatically cancelled and converted into the right to receive (i) an amount in cash equal to the excess of $38.00 in cash over the per-share exercise price of such option, without interest and less any applicable withholding taxes, and (ii) one non-transferable contingent value right (a "CVR") per underlying Ordinary Share entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent, in each case in accordance with the Transaction Agreement. No share options were exercised prior to the Effective Time. F3: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.89 · Expires 2034-06-25 | Direct | 0 |
Reported balance
After 2026-06-24 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-24 · Disposition to issuer · Disposed 48,000 · Balance 0 F1: On June 24, 2026, Eli Lilly and Company ("Parent"), through its wholly owned subsidiary LDH XV Corporation ("Purchaser"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the "Company") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the "Transaction Agreement"). F2: Pursuant to the Transaction Agreement, at the effective time of the Scheme of Arrangement, each outstanding share option, whether or not vested, was automatically cancelled and converted into the right to receive (i) an amount in cash equal to the excess of $38.00 in cash over the per-share exercise price of such option, without interest and less any applicable withholding taxes, and (ii) one non-transferable contingent value right (a "CVR") per underlying Ordinary Share entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent, in each case in accordance with the Transaction Agreement. No share options were exercised prior to the Effective Time. F3: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.43 · Expires 2035-06-20 | Direct | 0 |
Reported balance
After 2026-06-24 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-06-24 · Disposition to issuer · Disposed 40,000 · Balance 0 F1: On June 24, 2026, Eli Lilly and Company ("Parent"), through its wholly owned subsidiary LDH XV Corporation ("Purchaser"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the "Company") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the "Transaction Agreement"). F2: Pursuant to the Transaction Agreement, at the effective time of the Scheme of Arrangement, each outstanding share option, whether or not vested, was automatically cancelled and converted into the right to receive (i) an amount in cash equal to the excess of $38.00 in cash over the per-share exercise price of such option, without interest and less any applicable withholding taxes, and (ii) one non-transferable contingent value right (a "CVR") per underlying Ordinary Share entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent, in each case in accordance with the Transaction Agreement. No share options were exercised prior to the Effective Time. F3: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 24, 2026, Eli Lilly and Company ("Parent"), through its wholly owned subsidiary LDH XV Corporation ("Purchaser"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the "Company") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the "Transaction Agreement").
F2: Pursuant to the Transaction Agreement, at the effective time of the Scheme of Arrangement, each outstanding share option, whether or not vested, was automatically cancelled and converted into the right to receive (i) an amount in cash equal to the excess of $38.00 in cash over the per-share exercise price of such option, without interest and less any applicable withholding taxes, and (ii) one non-transferable contingent value right (a "CVR") per underlying Ordinary Share entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent, in each case in accordance with the Transaction Agreement. No share options were exercised prior to the Effective Time.
F3: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 30, 2017 Filed Aug 30, 2017 22:12 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 4,000 | $20.00 | $80,000.00 |
DisclosureSEC source: 0000899243-17-021279 · doc4.xml · nonDerivative · entry 2 Kulkarni Samarth · CIK 0001682019 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,893 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 28, 2017 Filed Aug 30, 2017 22:12 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 23,154 | $20.09 | $465,161.54 |
DisclosureSEC source: 0000899243-17-021279 · doc4.xml · nonDerivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,893 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transaction at prices ranging from $20.00 to $20.25, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff at the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 03, 2017 Filed May 5, 2017 22:39 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Options (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $16.21 | $0.00 |
DisclosureSEC source: 0000899243-17-012013 · doc4.xml · derivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Please See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Shares · 100,000 shares Expires 2027-05-03 F1 · derivative.exercise_date: This option was granted on May 3, 2017 with respect to 100,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning May 31, 2017. Read SEC document |
| April 27, 2017 Filed Apr 28, 2017 22:13 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Options (Right to Buy) · Derivative | 2,206 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-17-011231 · doc4.xml · derivative · entry 6 Kulkarni Samarth · CIK 0001682019 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,558 Underlying: Common Shares · 3,500 shares Expires 2025-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 321,712 Common Shares with 120,640 of the shares vested on August 1, 2016, the first anniversary of employment commencement, and the remainder vest in equal 36 monthly installments thereafter. Read SEC document |
| April 27, 2017 Filed Apr 28, 2017 22:13 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 2,206 | $16.78 | $37,022.86 |
DisclosureSEC source: 0000899243-17-011231 · doc4.xml · nonDerivative · entry 4 Kulkarni Samarth · CIK 0001682019 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,047 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.57 to $16.99, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 27, 2017 Filed Apr 28, 2017 22:13 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 2,206 | $1.81 | $3,992.86 |
DisclosureSEC source: 0000899243-17-011231 · doc4.xml · nonDerivative · entry 3 Kulkarni Samarth · CIK 0001682019 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,253 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 26, 2017 Filed Apr 28, 2017 22:13 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Options (Right to Buy) · Derivative | 3,275 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-17-011231 · doc4.xml · derivative · entry 5 Kulkarni Samarth · CIK 0001682019 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,764 Underlying: Common Shares · 3,275 shares Expires 2025-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 321,712 Common Shares with 120,640 of the shares vested on August 1, 2016, the first anniversary of employment commencement, and the remainder vest in equal 36 monthly installments thereafter. Read SEC document |
| April 26, 2017 Filed Apr 28, 2017 22:13 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 3,275 | $16.74 | $54,816.30 |
DisclosureSEC source: 0000899243-17-011231 · doc4.xml · nonDerivative · entry 2 Kulkarni Samarth · CIK 0001682019 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,047 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.57 to $17.00, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 26, 2017 Filed Apr 28, 2017 22:13 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 3,275 | $1.81 | $5,927.75 |
DisclosureSEC source: 0000899243-17-011231 · doc4.xml · nonDerivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,322 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 25, 2017 Filed Apr 25, 2017 23:36 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Options (Right to Buy) · Derivative | 5,115 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-17-010882 · doc4.xml · derivative · entry 9 Kulkarni Samarth · CIK 0001682019 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,039 Underlying: Common Shares · 5,115 shares Expires 2025-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 321,712 Common Shares with 120,640 of the shares vested on August 1, 2016, the first anniversary of employment commencement, and the remainder vest in equal 36 monthly installments thereafter. Read SEC document |
| April 25, 2017 Filed Apr 25, 2017 23:36 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 5,115 | $16.87 | $86,290.05 |
DisclosureSEC source: 0000899243-17-010882 · doc4.xml · nonDerivative · entry 6 Kulkarni Samarth · CIK 0001682019 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,047 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.70 to $17.10, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 25, 2017 Filed Apr 25, 2017 23:36 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 5,115 | $1.81 | $9,258.15 |
DisclosureSEC source: 0000899243-17-010882 · doc4.xml · nonDerivative · entry 5 Kulkarni Samarth · CIK 0001682019 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,162 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 24, 2017 Filed Apr 25, 2017 23:36 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Options (Right to Buy) · Derivative | 3,500 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-17-010882 · doc4.xml · derivative · entry 8 Kulkarni Samarth · CIK 0001682019 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,154 Underlying: Common Shares · 3,500 shares Expires 2025-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 321,712 Common Shares with 120,640 of the shares vested on August 1, 2016, the first anniversary of employment commencement, and the remainder vest in equal 36 monthly installments thereafter. Read SEC document |
| April 24, 2017 Filed Apr 25, 2017 23:36 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 3,500 | $16.46 | $57,619.45 |
DisclosureSEC source: 0000899243-17-010882 · doc4.xml · nonDerivative · entry 4 Kulkarni Samarth · CIK 0001682019 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,047 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.21 to $16.98, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 24, 2017 Filed Apr 25, 2017 23:36 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 3,500 | $1.81 | $6,335.00 |
DisclosureSEC source: 0000899243-17-010882 · doc4.xml · nonDerivative · entry 3 Kulkarni Samarth · CIK 0001682019 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,547 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 21, 2017 Filed Apr 25, 2017 23:36 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Options (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-17-010882 · doc4.xml · derivative · entry 7 Kulkarni Samarth · CIK 0001682019 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,654 Underlying: Common Shares · 3,000 shares Expires 2025-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 321,712 Common Shares with 120,640 of the shares vested on August 1, 2016, the first anniversary of employment commencement, and the remainder vest in equal 36 monthly installments thereafter. Read SEC document |
| April 21, 2017 Filed Apr 25, 2017 23:36 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 3,000 | $17.01 | $51,032.70 |
DisclosureSEC source: 0000899243-17-010882 · doc4.xml · nonDerivative · entry 2 Kulkarni Samarth · CIK 0001682019 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,047 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.86 to $17.24, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 21, 2017 Filed Apr 25, 2017 23:36 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 3,000 | $1.81 | $5,430.00 |
DisclosureSEC source: 0000899243-17-010882 · doc4.xml · nonDerivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,047 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 20, 2017 Filed Apr 21, 2017 20:32 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Options (Right to Buy) · Derivative | 2,800 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-17-010731 · doc4.xml · derivative · entry 7 Kulkarni Samarth · CIK 0001682019 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 311,654 Underlying: Common Shares · 2,800 shares Expires 2025-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 321,712 Common Shares with 120,640 of the shares vested on August 1, 2016, the first anniversary of employment commencement, and the remainder vest in equal 36 monthly installments thereafter. Read SEC document |
| April 20, 2017 Filed Apr 21, 2017 20:32 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 2,800 | $17.36 | $48,621.16 |
DisclosureSEC source: 0000899243-17-010731 · doc4.xml · nonDerivative · entry 5 Kulkarni Samarth · CIK 0001682019 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,047 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.17 to $17.60, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 20, 2017 Filed Apr 21, 2017 20:32 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 2,800 | $1.81 | $5,068.00 |
DisclosureSEC source: 0000899243-17-010731 · doc4.xml · nonDerivative · entry 4 Kulkarni Samarth · CIK 0001682019 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,847 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 20:32 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Options (Right to Buy) · Derivative | 7,258 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-17-010731 · doc4.xml · derivative · entry 6 Kulkarni Samarth · CIK 0001682019 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,454 Underlying: Common Shares · 7,258 shares Expires 2025-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 321,712 Common Shares with 120,640 of the shares vested on August 1, 2016, the first anniversary of employment commencement, and the remainder vest in equal 36 monthly installments thereafter. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 20:32 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 2,449 | $18.54 | $45,392.95 |
DisclosureSEC source: 0000899243-17-010731 · doc4.xml · nonDerivative · entry 3 Kulkarni Samarth · CIK 0001682019 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,047 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.05 to $18.99, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 20:32 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 4,809 | $17.54 | $84,361.40 |
DisclosureSEC source: 0000899243-17-010731 · doc4.xml · nonDerivative · entry 2 Kulkarni Samarth · CIK 0001682019 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,496 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.05 to $18.04, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 20:32 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 7,258 | $1.81 | $13,136.98 |
DisclosureSEC source: 0000899243-17-010731 · doc4.xml · nonDerivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,305 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.